Skip to content
Search

Latest Stories

UK monitoring 'subvariant' of coronavirus Delta strain: Govt

The government on Tuesday (October 19) said it was monitoring a subvariant of the Delta strain of the coronavirus, which has been seen in a growing number of cases.

Prime minister Boris Johnson's spokesman said the government was keeping a "close eye" on the AY.4.2 variant but said there was no evidence it spreads more easily.


"As you would expect, we are monitoring it closely and won't hesitate to take action if necessary," he told reporters.

Overall infection rates in Britain remain stubbornly high, despite high rates of vaccination, and on Monday nearly 50,000 new cases of Covid-19 were recorded.

Some scientists have suggested that measures to mitigate close-contact transmission, such as mask-wearing indoors, could be needed to prevent cases spiralling further.

Coronavirus restrictions were lifted across the country in July after three national lockdowns.

The rise has been attributed to high numbers of infections among schoolchildren, and prompted calls for a more wide-ranging booster jab programme to combat waning immunity.

Downing Street has acknowledged the rising numbers of positive tests, hospital admissions and deaths, but pointed to fluctuations in all three rates in recent months.

Francois Balloux, professor of computational systems biology at University College London, said AY.4.2 has two spike mutations found in other coronavirus variants and was first sequenced in April 2020.

The subvariant was "rare" outside Britain and there had been only three cases detected so far in the United States, he added.

"As AY.4.2 is still at fairly low frequency, a 10 percent increase in its transmissibility could have caused only a small number of additional cases.

"As such it hasn't been driving the recent increase in case numbers in the UK."

Bayroux, director of the UCL Genetics Institute, added: "This is not a situation comparable to the emergence of Alpha and Delta that were far more transmissible (50 per cent or more) than any strain in circulation at the time.

"Here we are dealing with a potential small increase in transmissibility that would not have a comparable impact on the pandemic."

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less